NuCana (NASDAQ:NCNA – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, MarketBeat reports.
Separately, Oppenheimer reiterated an “outperform” rating and set a $150.00 price target on shares of NuCana in a research note on Monday, August 19th.
Get Our Latest Report on NuCana
NuCana Stock Up 4.3 %
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc acquired a new stake in shares of NuCana plc (NASDAQ:NCNA – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund acquired 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana as of its most recent filing with the SEC. 44.00% of the stock is owned by institutional investors.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Further Reading
- Five stocks we like better than NuCana
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3M’s Turnaround Story Will Continue This Year
- 3 Fintech Stocks With Good 2021 Prospects
- Dollar General’s Stock: A Warning Sign for the Average American?
- Investing in Construction Stocks
- Polestar Lives to Fight Another Day After Q2 Earnings
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.